On July 13, 2026, Autonomix Medical, Inc. entered into a warrant inducement agreement with a holder of Series C warrants issued on November 19, 2025. The company reduced the exercise price of 428,731 existing warrants to $6.00 per share, expecting aggregate gross proceeds of approximately $2.6 million. In exchange, the company issued two new unregistered warrants (Series D-1 and Series D-2), each allowing the purchase of 428,731 shares at an exercise price of $5.75 per share with a 5.5-year term. Maxim Group LLC served as the solicitation agent and will receive a cash fee of 7.0% of the total proceeds plus expenses up to $15,000. Autonomix Medical is a medical device company that develops precision nerve-targeted treatments for diseases involving the nervous system.

Autonomix Medical, Inc. received a letter from Nasdaq notifying the company's common stock has regained compliance with the Bid Price Rule after the closing bid price remained at or above $1.00 per share for 10 consecutive business days from June 24, 2026, through July 8, 2026. Autonomix Medical, Inc. operates in the medical technology industry and develops diagnostic tools for gastrointestinal health.

Autonomix Medical, Inc. has announced a 1-for-21 reverse stock split of its common stock, effective June 24, 2026. The split will reduce the number of outstanding shares from 11,409,344 to approximately 542,000 shares. Autonomix Medical, Inc. operates in the medical technology industry and develops specialized medical devices for diagnostic and diagnostic-related services.